Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

Alexander Stein(Universität Hamburg), Dirk Arnold(Asklepios Klinik Altona), Thomas Wolff(University of Basel), Andreas Kirsch, E. Kettner(University Hospital Magdeburg), J. Zimber, Albrecht Kretzschmar(Roche (Switzerland)), Dirk Behringer(Augusta-Kranken-Anstalt), Karl-Heinz Pflüger(Evangelisches Diakoniekrankenhaus), Susanna Hegewisch‐Becker

BMC Cancer

October 4, 2013

10.1186/1471-2407-13-454

Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2015|1.3k

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2016|1.1k

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

|Annals of Oncology|2017|829